Physician profile
Rooptaz Sibia
NPI 1770501868
$6,949.83
in general payments reported to CMS, 2019-2025
42 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,126 · 2020: $688 · 2021: $1,142 · 2022: $1,629 · 2023: $886 · 2024: $697 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $967.06 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Becton, Dickinson and Company | $650.00 | 2019-2022 | |
| Pfizer INC. | $595.58 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $483.42 | 2019-2023 | Livalo |
| Astrazeneca Pharmaceuticals Lp | $445.04 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $387.09 | 2019-2025 | Veozah, Myrbetriq |
| Mckesson Medical-Surgical, INC. | $362.00 | 2022 | |
| Abbvie INC. | $329.47 | 2019-2025 | Ubrelvy, Synthroid, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $273.05 | 2021-2025 | |
| Amarin Pharma, INC. | $262.29 | 2019-2021 | |
| Exact Sciences Corporation | $239.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Atricure, INC. | $214.80 | 2023 | |
| Janssen Pharmaceuticals, INC | $206.13 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $198.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $152.07 | 2022-2025 | Mounjaro, Zepbound |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rooptaz Sibia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.